Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vesicular Monoamine Transporter Type 2 (VMAT2) is an essential neuronal protein encoded by SLC18A2 that loads key neurotransmitters into synaptic vesicles using a proton-driven mechanism. It plays crucial roles in brain signaling regulation and serves as an important drug target for several neuropsychiatric conditions due to its role controlling availability/release of major biogenic amines.
Inhibition of vesicular monoamine uptake leading to decreased neurotransmitter release and increased cytosolic breakdown.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vesicular Monoamine Transporter Type 2 (VMAT2).